CG Oncology (NASDAQ:CGON) and Fresh Tracks Therapeutics (NASDAQ:FRTX) Head-To-Head Contrast

Fresh Tracks Therapeutics (NASDAQ:FRTX) and CG Oncology (NASDAQ:CGON) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability.

Profitability

This table compares Fresh Tracks Therapeutics and CG Oncology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fresh Tracks Therapeutics	N/A	N/A	N/A
CG Oncology	-10,642.98%	-18.97%	-15.36%

Valuation and Earnings

This table compares Fresh Tracks Therapeutics and CG Oncology”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fresh Tracks Therapeutics	$10.06 million	0.45	-$5.69 million	($1.41)	-0.53
CG Oncology	$684,000.00	2,894.05	-$48.61 million	N/A	N/A

Fresh Tracks Therapeutics has higher revenue and earnings than CG Oncology.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Fresh Tracks Therapeutics and CG Oncology, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fresh Tracks Therapeutics	0	0	0	0	0.00
CG Oncology	0	0	8	1	3.11

CG Oncology has a consensus price target of $63.88, indicating a potential upside of 118.23%. Given CG Oncology’s stronger consensus rating and higher probable upside, analysts clearly believe CG Oncology is more favorable than Fresh Tracks Therapeutics.

Institutional and Insider Ownership

25.0% of Fresh Tracks Therapeutics shares are held by institutional investors. Comparatively, 26.6% of CG Oncology shares are held by institutional investors. 0.2% of Fresh Tracks Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

About Fresh Tracks Therapeutics

Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

About CG Oncology

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.